Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced that its Phase 2 trial for ETD001, the Company's lead candidate for treatment of cystic fibrosis (CF), achieved its primary efficacy outcome.

Enterprise’s Phase II trial of ETD001 meets primary endpoint in pwCF

Enterprise Therapeutics has announced that its Phase II clinical trial of ETD001, an investigational inhaled ENaC blocker in pwCF, has met its primary efficacy outcome.The post Enterprise’s Phase II trial of ETD001 meets primary endpoint in pwCF appeared first on Clinical Trials Arena.

Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis

Lead candidate ETD001 delivers significant lung function improvement